Abstract 809P
Background
Gynecological cancer may have severe implications in women, as these diagnoses are likely to have negative consequences on mental health and socioeconomic status. We used the Swedish national population and healthcare registries to assess the association between diagnosis of endometrial or cervical cancer and risk for mental disorders, as well as for socioeconomic consequences.
Methods
We performed a population-based nested case-control study based on more than 5 million women in Sweden, identifying 6,060 cases of cervical cancer and 17,932 cases of endometrial cancer diagnosed during 2006-2018. Each cancer case was matched with five healthy controls randomly selected from the population born in the same year. Data on comprehensive set of mental disorders, loss of employment, early retirement or need for sickness benefit, family receipt of financial assistance, decrease of individual income and family income before versus after cancer diagnosis were retrieved from population registries. Conditional logistic regression and stratified Cox regression models with confounder adjustment were conducted to estimate odds ratios (OR) and 95% confidence intervals (CI).
Results
Mental disorders were prevalent to a moderate degree before diagnosis among cervical cancer patients, but less prevalent in endometrial cancer patients. After cancer diagnosis, incident (i.e. new) mental disorders started emerging within the first 2-5 years and then persisted. The risk was higher following cervical cancer (OR=3.7, 95% CI=3.5-4.1) as compared to endometrial cancer (OR=2.1, 95% CI=2.0-2.2). Before cancer diagnosis, economic status was comparable between cancer patients and control women. Financial assistance and income decrease rose early after diagnosis, with 1.2-2.1 times increased risk among cancer patients. Unemployment, early retirement and need for sickness benefit doubled from two years after cancer diagnosis and onwards. Impact was more pronounced among cervical cancer patients.
Conclusions
Women with cervical cancer and endometrial cancer are affected mentally and financially after the cancer diagnosis. The impact is more pronounced among cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD Sweden.
Disclosure
J. Wang, K. Sundström: Financial Interests, Institutional, Research Funding: MSD. A.L. Feldman: Financial Interests, Institutional, Other: Has been part of research collaborations within partnership programs between Karolinska Institutet and respectively MSD Sweden/Merck and Janssen Pharmaceutica NV. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11